NeoGenomics (Nasdaq:NEO) - Aandelenkoers, Nieuws & Analyse

NEO Overzicht aandelen

NeoGenomics, Inc. exploiteert een netwerk van laboratoria voor kankeronderzoek in de Verenigde Staten en het Verenigd Koninkrijk. Meer informatie

NEO fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 76.2% onder onze schatting van de reële waarde

De omzet zal naar verwachting met 10.08% per jaar groeien

Risicoanalyse

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

NeoGenomics, Inc. Concurrenten

Addus HomeCare

NasdaqGS:ADUS

US$2.2b

GeneDx Holdings

NasdaqGS:WGS

US$1.9b

Astrana Health

NasdaqCM:ASTH

US$2.0b

Agiliti

NYSE:AGTI

US$1.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor NeoGenomics
Historische aandelenkoersen
Huidige aandelenkoers	US$15.39
52 Week Hoogtepunt	US$21.22
52 Week Laag	US$12.77
Bèta	1.18
11 maand verandering	16.41%
3 maanden verandering	-7.62%
1 Jaar Verandering	-19.40%
33 jaar verandering	-59.10%
5 jaar verandering	-40.35%
Verandering sinds IPO	491.92%

Recent nieuws en updates

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Oct 16

Recent updates

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Oct 16

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

Aug 01

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

Jul 16

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Apr 18

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Jan 10

NeoGenomics: Market Punishment Continues, But Looks Justified

Sep 30

NeoGenomics grants CEO restricted shares, stock options

Aug 17

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Aug 10

NeoGenomics rises ~14% on strong Q2 result

Aug 09

NeoGenomics gets new CEO

Jul 21

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

Jun 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Apr 22

Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral

Apr 08

Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Feb 11

Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

Jan 07

NeoGenomics: Gambling On Growth

Dec 16

Rendement voor aandeelhouders

	NEO	US Healthcare	US Markt
7D	-2.5%	-1.2%	-1.0%
1Y	-19.4%	2.5%	30.3%

Rendement versus industrie: NEO presteerde slechter dan de US Healthcare -sector, die het afgelopen jaar een rendement van 2.5 % opleverde.

Rendement versus markt: NEO presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.3 % opleverde.

Prijsvolatiliteit

Is NEO's price volatile compared to industry and market?
NEO volatility
NEO Average Weekly Movement	5.6%
Healthcare Industry Average Movement	7.0%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: NEO heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van NEO is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2001	2,100	Chris Smith	www.neogenomics.com

NeoGenomics, Inc. exploiteert een netwerk van op kanker gerichte testlaboratoria in de Verenigde Staten en het Verenigd Koninkrijk. Het is actief via de segmenten Klinische Diensten en Geavanceerde Diagnostiek. Het bedrijf biedt testdiensten aan ziekenhuizen, academische centra, pathologen, oncologen, clinici, farmaceutische bedrijven en klinische laboratoria.

NeoGenomics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van NeoGenomics zich tot de beurswaarde?
NEO fundamentele statistieken
Marktkapitalisatie	US$1.97b
Inkomsten(TTM)	-US$77.73m
Inkomsten(TTM)	US$644.12m

3.1x

P/S-verhouding

-25.4x

Koers/Winstverhouding

Is NEO overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
NEO resultatenrekening (TTM)
Inkomsten	US$644.12m
Kosten van inkomsten	US$363.69m
Brutowinst	US$280.43m
Overige uitgaven	US$358.16m
Inkomsten	-US$77.73m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.61
Brutomarge	43.54%
Nettowinstmarge	-12.07%
Schuld/Eigen Vermogen Verhouding	59.5%

Hoe presteerde NEO op de lange termijn?

Bekijk historische prestaties en vergelijking

NEO Overzicht aandelen

Beloningen

Risicoanalyse

NeoGenomics, Inc. Concurrenten

NasdaqGS:ADUS

US$2.2b

NasdaqGS:WGS

US$1.9b

NasdaqCM:ASTH

US$2.0b

NYSE:AGTI

US$1.4b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings: EPS exceeds analyst expectations

Neogenomics, Inc. Revises Full-Year 2024 Guidance

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. to Report Q3, 2024 Results on Nov 05, 2024

NeoGenomics, Inc. Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia

Consensus EPS estimates fall by 15%

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations

Neogenomics, Inc. Revises Full-Year 2024 Guidance

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. to Report Q3, 2024 Results on Nov 05, 2024

NeoGenomics, Inc. Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia

Consensus EPS estimates fall by 15%

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

NeoGenomics, Inc. Revises Earnings Guidance for the Full-Year 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. to Report Q2, 2024 Results on Jul 29, 2024

NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO

NeoGenomics, Inc. Reaffirms Consolidated Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics

NeoGenomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024

NeoGenomics, Inc., Annual General Meeting, May 23, 2024

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Price target increased by 7.2% to US$21.55

Full year 2023 earnings: EPS exceeds analyst expectations

NeoGenomics, Inc. Provides Earnings Guidance for the Year 2024

NeoGenomics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

NeoGenomics Laboratories, Inc. to Appeal Ruling

Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Consensus estimates of losses per share improve by 11%

NeoGenomics, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Neogenomics, Inc. Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios

NeoGenomics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

NeoGenomics, Inc. Expands Board of Directors with Appointments of Three Independent Directors

NeoGenomics, Inc.'s RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

NeoGenomics, Inc. and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

NeoGenomics, Inc. to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

Price target increased by 7.7% to US$21.64

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.25 loss per share (vs US$0.40 loss in 1Q 2022)

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Full year 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics, Inc. Announces Results of a New Study of the RaDaR Assay in Patients with Muscle-Invasive Bladder Cancer

Neogenomics, Inc. Announces Resignation of David J. Daly to Board of Directors

The Klein Law Firm Announces Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Neogenomics, Inc. Shareholders

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Gibbs Law Group Announces Files Class Action Lawsuit Against NeoGenomics Inc

NeoGenomics, Inc. Announces Executive Changes

Neogenomics, Inc. Announces Radar Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

NeoGenomics, Inc. Appoints Melody Harris as President, Enterprise Operations effective December 5, 2022

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics Appoints David Perez to its Board of Directors

NeoGenomics, Inc. Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch

NeoGenomics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

NeoGenomics: Market Punishment Continues, But Looks Justified

NeoGenomics grants CEO restricted shares, stock options

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt